72 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 60 of 72 clinical reviews.
A comparison of compounded dulaglutide versus branded Trulicity, covering FDA approval status, clinical trial evidence from REWIND, safety differences, cost, and who qualifies for each option.
A complete guide to Aetna (CVS Health) Trulicity coverage, prior authorization criteria, step therapy requirements, formulary tier, appeal steps, and cost-saving options for dulaglutide in 2024.
A complete guide to Cigna coverage for Trulicity (dulaglutide), including formulary tier, prior authorization criteria, step therapy requirements, denial appeals, and manufacturer savings options.
Find out whether Humana covers Trulicity (dulaglutide) for type 2 diabetes, what formulary tier it sits on, prior-authorization requirements, step-therapy rules, and how to appeal a denial.
A detailed guide to Kaiser Permanente's Trulicity formulary status, prior authorization requirements, step-therapy rules, appeal process, and cost options for dulaglutide in 2024.
Medicare Advantage plans rarely cover Trulicity (dulaglutide) for weight loss but often do for type 2 diabetes. Learn the exact formulary tiers, prior-authorization criteria, step-therapy rules, and appeal steps that apply in 2025.
A guide to how state Medicaid programs generally handle Trulicity (dulaglutide) coverage, prior authorization, step therapy, and appeals for type 2 diabetes and, in some states, weight management. State rules vary and require direct verification.
TRICARE covers Trulicity (dulaglutide) for type 2 diabetes with prior authorization. Learn the formulary tier, step therapy rules, PA criteria, appeal process, and out-of-pocket costs for military beneficiaries.
A guide to Trulicity (dulaglutide) self-injection technique, covering pen anatomy, site selection, injection steps, needle-free design, and how to avoid common errors.
Evidence-based dosing guide for dulaglutide (Trulicity) in adolescents aged 12, 17 with type 2 diabetes. Covers FDA-approved doses, titration schedules, safety monitoring, and clinical trial data.
Evidence-based Trulicity (dulaglutide) dosing guide for adults aged 30, 49 with type 2 diabetes. Covers starting dose, titration schedule, injection technique, missed-dose rules, and real-world clinical considerations.
A guide to using dulaglutide (Trulicity) after bariatric surgery, covering pharmacokinetics, dosing, evidence from REWIND and other trials, and practical prescribing considerations for post-bariatric patients with type 2 diabetes.
A clinician-level review of dulaglutide (Trulicity) use in patients with autoimmune conditions, covering thyroid disease, IBD, lupus, RA, and safety signals from REWIND and post-marketing data.
A clinician-level review of how dulaglutide (Trulicity) affects sexual function in men and women with type 2 diabetes, covering the REWIND trial, hormonal pathways, erectile dysfunction, libido changes, and practical management guidance.
A primary-literature analysis of dulaglutide's effect on cognition, brain health, and dementia risk in type 2 diabetes, including REWIND trial data and mechanistic research.
Evidence-based guide to dulaglutide (Trulicity) dosing in geriatric patients, covering renal adjustments, falls risk, deprescribing, and monitoring for adults 65+.
How to dose Trulicity (dulaglutide) in adults aged 50, 64, including titration schedules, renal adjustments, cardiovascular benefits from REWIND, and polypharmacy considerations.
A guide to dulaglutide (Trulicity) dosing for young adults aged 18, 29 with type 2 diabetes, covering starting doses, titration schedules, injection technique, fertility considerations, and cardiovascular evidence from the REWIND trial.
Evidence-based guide to dulaglutide (Trulicity) dosing in patients with hepatic impairment, including pharmacokinetic data, clinical recommendations, and liver safety monitoring.
Evidence-based guide to dulaglutide (Trulicity) dosing across all stages of renal impairment, including CKD stages 3-5 and dialysis, with FDA label data, REWIND renal outcomes, and AWARD trial pharmacokinetics.
Evidence-based guide to dulaglutide (Trulicity) food and supplement interactions, including effects on nutrient absorption, alcohol, fiber, and common vitamins.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes. Learn about REWIND trial results, dosing protocols, A1c reduction data, and cardiovascular benefits.
A clinical deep dive into the future of dulaglutide (Trulicity), including Eli Lilly's GLP-1 pipeline, next-generation agonists, oral formulations, and combination therapies in development.
Evidence-based guide to using dulaglutide (Trulicity) in transplant recipients, people living with HIV, older adults, and other special populations. Includes dosing, safety data, and clinical considerations.
A clinical deep-dive into Trulicity's manufacturing process, supply chain structure, FDA shortage timelines, and what the 2024 discontinuation means for patients on dulaglutide.
Evidence-based monitoring guide for adults aged 30 to 49 taking Trulicity (dulaglutide), including HbA1c targets, renal panels, thyroid surveillance, cardiovascular markers, and GI safety checks.
Evidence-based monitoring protocol for dulaglutide (Trulicity) in geriatric patients 65+, covering renal function, hypoglycemia screening, GI tolerability, fall risk, and deprescribing timelines.
A clinical review of dulaglutide off-label applications including MASLD, obesity, PCOS, and neuroprotection, graded by strength of evidence from RCTs and guideline support.
A clinical review of dulaglutide (Trulicity) patent filings, exclusivity windows, biosimilar development, and projected generic availability for patients with type 2 diabetes.
Evidence-based guide to dulaglutide (Trulicity) use in children under 12, including current FDA labeling, off-label considerations, weight-based dosing data, and safer alternatives for pediatric type 2 diabetes.
A comprehensive clinical guide to monitoring dulaglutide (Trulicity) in pediatric patients under age 12, covering FDA labeling, dosing, growth surveillance, safety labs, and GI adverse effects.
Dulaglutide (Trulicity) is not FDA-approved for children under 12. Review the clinical evidence, safety gaps, growth concerns, and monitoring considerations for pediatric GLP-1 receptor agonist use.
A guide to dulaglutide (Trulicity) use during pregnancy and breastfeeding, covering FDA labeling, animal data, GLP-1 receptor biology, and evidence-based alternatives for managing type 2 diabetes in reproductive-age women.
A physician-level review of dulaglutide (Trulicity) real-world evidence from registries, claims databases, and post-marketing studies, including REWIND cardiovascular data and adherence outcomes.
A guide to dulaglutide (Trulicity) safety in adults aged 50, 64, covering cardiovascular outcomes, GI tolerability, hypoglycemia risk, polypharmacy, and the REWIND trial data.
A guide to dulaglutide safety in adolescents with type 2 diabetes, covering FDA approval status, trial data, dosing, growth monitoring, and contraindications for ages 12, 17.
A guide to dulaglutide (Trulicity) safety for adults aged 30 to 49, covering GI side effects, cardiovascular data from REWIND, pancreatitis risk, thyroid warnings, and practical monitoring advice.
A guide to dulaglutide (Trulicity) safety for young adults ages 18, 29, covering trial evidence, side effects, fertility, contraception, and dosing guidance with primary-source citations.
A comprehensive review of dulaglutide (Trulicity) safety signals, FDA regulatory actions, boxed warnings, postmarketing surveillance findings, and clinical trial safety data from REWIND and AWARD trials.
A clinical deep-dive into how dulaglutide (Trulicity) changes appetite, food cravings, and eating behavior in type 2 diabetes. Includes trial data, mechanism, dose effects, and practical management.
A physician-level review of dulaglutide (Trulicity) and cancer risk, covering thyroid, pancreatic, and colorectal signals from REWIND, FDA labeling, and post-marketing surveillance data.
A deep-dive into dulaglutide's long-term cardiovascular effects, anchored in the REWIND trial and supporting literature. Learn what a 12% MACE reduction means clinically, who benefits most, and how dulaglutide compares to other GLP-1 receptor agonists.
A citation-dense guide to every clinically significant drug-drug interaction with Trulicity (dulaglutide): mechanisms, affected drug classes, management strategies, and the REWIND cardiovascular evidence base.
A detailed cost and efficacy comparison of Trulicity (dulaglutide) against other GLP-1 receptor agonists including Ozempic, Mounjaro, Victoza, and Rybelsus, with trial data and pricing analysis.
Trulicity (dulaglutide) received EMA marketing authorization on November 21, 2014, with active status across the EU, US, Canada, and UK today.
A GRADE-level analysis of dulaglutide (Trulicity) clinical evidence, covering cardiovascular outcomes, glycemic efficacy, weight, safety, and how the data stacks up for shared decision-making in type 2 diabetes.
A guide to using dulaglutide (Trulicity) for metabolic syndrome: trial evidence, dosing schedules, cardiovascular outcomes, and practical protocols.
Dulaglutide (Trulicity) is not FDA-approved for NAFLD or MASLD, but trial data suggest it reduces hepatic fat and liver enzymes in patients with type 2 diabetes. Learn what the evidence shows, how it is dosed, and who may benefit.
A guide to using dulaglutide (Trulicity) for prediabetes: off-label rationale, dosing, trial evidence from REWIND and AWARD studies, side effects, and how to talk to your doctor.
A guide to dulaglutide (Trulicity) safety in adults aged 65 and older, covering renal function, falls risk, GI tolerability, drug interactions, cardiovascular evidence from REWIND, and deprescribing thresholds.
A guide to dulaglutide (Trulicity) effects on hair and skin, covering clinical trial data, proposed mechanisms, and what patients can expect.
A deep-dive into the scientific origin of dulaglutide (Trulicity): from early GLP-1 receptor agonist research and Fc-fusion engineering through the AWARD trials, FDA approval, and the REWIND cardiovascular outcomes trial.
A clinical deep-dive into how dulaglutide (Trulicity) affects liver enzymes, hepatic fat, and NAFLD/MASH. Covers REWIND trial data, ALT/AST findings, and prescribing guidance for patients with liver disease.
How dulaglutide (Trulicity) works: GLP-1 receptor binding, insulin secretion, glucagon suppression, gastric slowing, and what the REWIND cardiovascular trial does and does not establish.
A clinician-level review of how dulaglutide (Trulicity) affects mental health and mood, covering GLP-1 receptor signaling in the brain, trial data, FDA safety communications, and practical monitoring guidance.
Evidence-based protocol for managing a missed Trulicity (dulaglutide) dose, including timing thresholds, double-dose risks, and how to get back on schedule safely.
Complete evidence-based monitoring schedule for Trulicity (dulaglutide) including baseline labs, follow-up intervals, and recommended exams from ADA and Endocrine Society guidelines.
Evidence-based strategies to preserve lean mass while on Trulicity (dulaglutide), including resistance training protocols, protein targets, and monitoring checkpoints reviewed by HealthRX.com physicians.
A guide to dulaglutide (Trulicity) overdose: symptoms, mechanisms, treatment protocols, and when to seek emergency care.
A clinician-level guide to dulaglutide (Trulicity) pharmacogenomics, covering GLP-1R variants, TCF7L2 genotype effects, metabolic enzyme polymorphisms, cardiovascular outcomes by ancestry, and how genetic testing might one day personalize GLP-1 therapy.
Showing the first 60 matches among the loaded articles. Use the page links below to browse the complete library.